Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 15Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neoplasms 2Neoplasm Metastasis 2Brain Neoplasms 2Uveal Melanoma 1Patient Preference 1Melanoma, Cutaneous Malignant 1Lymphoma 1Locally Advanced Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Ipilimumab 17tremelimumab 9Nivolumab 9durvalumab 8pembrolizumab 6Paclitaxel 5Carboplatin 4Capecitabine 4Bevacizumab 4lenvatinib 3spartalizumab 2balstilimab 2Radiotherapy 2Radiation 2Pemetrexed 2Oxaliplatin 2Doxorubicin 2Docetaxel 2Cisplatin 2CTLA-4 Antigen 2Blood Specimen Collection 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1relatlimab 1poly ICLC 1osimertinib 1folfirinox 1eribulin 1envafolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Opdualag × Clear all
NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

University of Pittsburgh

Phase 2 Completed
20 enrolled 13 charts
Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡